1-15 of 15
Diana Graus-Porta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Grainne Kerr, Kathleen Sprouffske, Tina Yuan, David Ruddy, Morgane Meistertzheim, Malika Kazic-Legueux, Tina Kottarathil, Michelle Piquet, Yichen Cao, Laetitia Martinuzzi-Duboc, Alexandra Buhles, Flavia Adler, Salvatore Mannino, Luca Tordella, Laurent Sansregret, Sauveur-Michel Maira, Diana Graus Porta, Carmine Fedele, Saskia M. Brachmann
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4130–4141.
https://doi.org/10.1158/0008-5472.CAN-23-1127
Published: 15 December 2023
View article titled, CRISPR Screening Identifies Mechanisms of Resistance to KRAS<sup>G12C</sup> and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
Open the PDF for CRISPR Screening Identifies Mechanisms of Resistance to KRAS<sup>G12C</sup> and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

Andreas Weiss, Hans Voshol, Diana Graus Porta, Carmine Fedele, Dario Sterker, Ruben De Kanter, Rowan Stringer, Toni Widmer, Alice Loo, Daniel A. Guthy, Kim S. Beyer, Nils Ostermann, Catherine LeBlanc, Marc Gerspacher, Andrea Vaupel, Richard Sedrani, Frederic Zecri, Saveur-Michel Maria, Francesco Hofmann, Peter Hammerman, Jeff Engelman, Edwige Lorthiois, Simona Cotesta, Saskia M. Brachmann
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4026.
https://doi.org/10.1158/1538-7445.AM2022-4026
Published: 15 June 2022
View article titled, Abstract 4026: JDQ443, a covalent inhibitor of KRAS<sup>G12C</sup> with a novel binding mode, shows broad antitumor activity in KRAS<sup>G12C</sup> preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6
Journal Articles

Abstract 394: In vivo shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for BRAF-mutant colorectal cancer

Hyo-eun C. Bhang, Matthew T. DiMare, David P. Kodack, Lujian Tan, Grainne Kerr, Viveksagar Krishnamurthy Radhakrishna, Javad Golji, David A. Ruddy, Tina Yuan, Matthew J. Niederst, Joshua M. Korn, Diana Graus Porta, Peter S. Hammerman, Jeffrey A. Engelman, Tinya Abrams, Juliet Williams
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 394.
https://doi.org/10.1158/1538-7445.AM2019-394
Published: 01 July 2019
View article titled, Abstract 394: <em>In vivo</em> shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for <em>BRAF</em>-mutant colorectal cancer
Journal Articles

Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC

Diana Graus Porta, Andreas Weiss, Robin A. Fairhurst, Markus Wartmann, Christelle Stamm, Flavia Reimann, Alexandra Buhles, Jaqueline Kinyamu-Akunda, Dario Sterker, Masato Murakami, Youzhen Wang, Jeffrey Engelman, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2098.
https://doi.org/10.1158/1538-7445.AM2017-2098
Published: 01 July 2017
View article titled, Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC
Journal Articles

Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors

Andreas Weiss, Diana Graus Porta, Flavia Reimann, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Jacqueline Kinyamu-Akunda, Dario Sterker, Masato Murakami, Markus Wartmann, Youzhen Wang, Jeffrey A. Engelman, Francesco Hofmann, Wiliam R. Sellers
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2103.
https://doi.org/10.1158/1538-7445.AM2017-2103
Published: 01 July 2017
View article titled, Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors
Journal Articles

Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression

Stephen L. Chan, Chia-Jui Yen, Martin Schuler, Chia-Chi Lin, Su Pin Choo, Karl-Heinz Weiss, Andreas Geier, Takuji Okusaka, Ho Yeong Lim, Teresa Macarulla, Andrew X. Zhu, Tomoyuki Kakizume, Yi (Gary) Gu, Diana Graus Porta, Andrea P. Myers, Jean-Pierre Delord
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT106.
https://doi.org/10.1158/1538-7445.AM2017-CT106
Published: 01 July 2017
View article titled, Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression
Journal Articles

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

Lecia V. Sequist, Phillippe Cassier, Andrea Varga, Josep Tabernero, Jan H. Schellens, Jean-Pierre Delord, Patricia LoRusso, D. Ross Camidge, Manuel Hidalgo Medina, Martin Schuler, Mario Campone, G. Gary Tian, Steven Wong, Jesus Corral, Randi Isaacs, Suman K. Sen, Diana Graus Porta, Swarupa G. Kulkarni, Caroline Lefebvre, Jürgen Wolf
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT326.
https://doi.org/10.1158/1538-7445.AM2014-CT326
Published: 01 October 2014
View article titled, Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
Journal Articles

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Sebastien Jeay, Joerg Berghausen, Nicole Buschmann, Patrick Chène, Robert Cozens, Dirk Erdmann, Stéphane Ferretti, Pascal Furet, Tobias Gabriel, François Gessier, Diana Graus-Porta, Francesco Hofmann, Philipp Holzer, Moriko Ito, Edgar Jacoby, Michael Jensen, Joerg Kallen, Marc Lang, Joanna Lisztwan, Masato Murakami, Carole Pissot-Soldermann, Stephan Ruetz, Caroline Rynn, Dario Sterker, Stefan Stutz, Thérèse Valat, Marion Wiesmann, Keiichi Masuya
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1797.
https://doi.org/10.1158/1538-7445.AM2014-1797
Published: 01 October 2014
View article titled, Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial
Journal Articles

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Sebastien Jeay, Swann Gaulis, Stéphane Ferretti, Geneviève Albrecht, Louise Barys, Daniel Guthy, Ensar Halilovic, Moriko Ito, Masato Murakami, Astrid Pornon, Stephan Ruetz, Kavitha Venkatesan, Jianjun Yu, Michael Jensen, Marion Wiesmann, Jens Wuerthner, Diana Graus-Porta
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2909.
https://doi.org/10.1158/1538-7445.AM2014-2909
Published: 01 October 2014
View article titled, Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models
Journal Articles

Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro

Richard S. Finn, Alex Aleshin, Danyun Zhao, Lee Anderson, Charles Ginther, Judy Dering, Michael Shi, Diana Graus Porta, Roanld W. Busuttil, Dennis J. Slamon
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3858.
https://doi.org/10.1158/1538-7445.AM2012-3858
Published: 15 April 2012
View article titled, Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 <em>in vitro</em>
Journal Articles

Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials

Diana Graus Porta, Vito Guagnano, Christelle Stamm, Simon Woehrle, Audrey Kauffmann, Yao Yao, Thomas Brümmendorf, Vincent Bordas, Mickaël Le Douget, Yun Zhang, Zhi Chen, Moriko Ito, Fang Li, John Monahan, Alex Gaither, Jason Borawski, Christopher J. Wilson, Kavitha Venkatesan, Francesco Hofmann, William Sellers
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 854.
https://doi.org/10.1158/1538-7445.AM2012-854
Published: 15 April 2012
View article titled, Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials
Journal Articles

Abstract 3575: Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer

Michael M. Shi, Ronald Linnartz, Richard Versace, Joseph Brueggen, Christian Chatenay-Rivauday, Christelle Stamm, Margaret Dugan, Diana Graus Porta
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3575.
https://doi.org/10.1158/1538-7445.AM2011-3575
Published: 15 April 2011
View article titled, Abstract 3575: Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer
Journal Articles

Abstract #4766: FGFR genetic alterations or constitutive pathway activation define sensitivity to TKI258, an FGFR kinase inhibitor

Diana Graus Porta, Christelle Stamm, Sandra Mollé, Sabine Zumstein-Mecker, Yao Yao, Giordano Caponigro, Marta Cortés-Cros, Carlos Garcia-Echeverria
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4766.
Published: 01 May 2009
View article titled, Abstract #4766: FGFR genetic alterations or constitutive pathway activation define sensitivity to TKI258, an FGFR kinase inhibitor
Journal Articles

TKI258, a multi-targeted receptor tyrosine kinase (RTK) inhibitor, is efficacious in preclinical models of bladder cancer

Diana Graus Porta, Sandra Molle, Christelle Stamm, Michael Rugaard Jensen, Christian Chatenay-Rivauday, Josef Brueggen, Tinya Abrams, Michel Faure, Daniel Menezes, Nancy Pryer, Katherine Rendahl, Paul Renhowe, Carlos Garcia-Echeverria
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4888.
Published: 01 May 2008
View article titled, TKI258, a multi-targeted receptor tyrosine kinase (RTK) inhibitor, is efficacious in preclinical models of bladder cancer
Journal Articles

Neu Differentiation Factor Induces ErbB2 Down-Regulation and Apoptosis of ErbB2-overexpressing Breast Tumor Cells

John M. Daly, Christian B. Jannot, Roger R. Beerli, Diana Graus-Porta, Francisca G. Maurer, Nancy E. Hynes
Journal: Cancer Research
Cancer Res (1997) 57 (17): 3804–3811.
Published: 01 September 1997
View article titled, Neu Differentiation Factor Induces ErbB2 Down-Regulation and Apoptosis of ErbB2-overexpressing Breast Tumor Cells
Open the PDF for Neu Differentiation Factor Induces ErbB2 Down-Regulation and Apoptosis of ErbB2-overexpressing Breast Tumor Cells in another window